News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
August 2017
-
Media ReleaseMultimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
-
Media ReleaseNovartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
-
Media ReleaseNovartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones- elevateMS study allows researchers to collect sensor-based movement data and symptoms directly from participants without the need for clinic visits- Study aims to improve understanding of daily…
-
Media ReleaseNovartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones
July 2017
-
Media ReleaseFDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for NovartisAMG 334 (erenumab) is an investigational therapy with a novel mechanism of action for migraine prevention for patients with high unmet needMigraine is associated with pain, disability and nearly $25…
-
Media ReleaseFDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis
-
Media ReleaseNovartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis- 5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis(1)- Data planned to be presented at a…
-
Media ReleaseNovartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
June 2017
-
Media ReleaseNovartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL- 83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data- Data evaluating 63…
-
Media ReleaseNovartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
-
Media ReleaseNovartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL-- At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff-- Best ORR was 59%, with 43…
-
Media ReleaseNovartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
Pagination
- ‹ Previous page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- …
- 56
- › Next page